HCW Biologics Provides New Update on Tetra-Valent ICI Program
New Immune Checkpoint Inhibitor: HCW Biologics presented updated data on its second-generation pembrolizumab-based immune checkpoint inhibitor, HCW11-040, at the SITC2025 meeting, showcasing its enhanced efficacy over first-generation inhibitors.
Mechanism of Action: HCW11-040 incorporates additional moieties that neutralize TGF-beta and activate effector immune cell responses, significantly expanding progenitor exhausted T cells compared to existing therapies.
Enhanced Treatment Outcomes: The new inhibitor demonstrates superior activation of human peripheral blood lymphocytes and memory T cells, leading to improved anti-tumor activity against pancreatic cancer and leukemia in organoid models.
Safety Profile: HCW11-040 shows a favorable safety profile, with no evidence of excessive inflammatory responses in immune cells following subcutaneous administration.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on HCWB
About HCWB
About the author
HCW Biologics Inc. (NASDAQ: HCWB) Engages in Virtual Investor "What This Means" Discussion
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to combat age-related diseases and chronic inflammation, utilizing their TRBC drug discovery platform.
Product Candidate: The company's lead product, HCW11-040, is a second-generation immune checkpoint inhibitor that combines pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, showing promise in expanding exhausted T cells without side effects.
Upcoming Presentation: HCW Biologics will present data on HCW11-040 at the 40th annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, highlighting its potential as a novel tetra-specific immunotherapeutic.
Forward-Looking Statements: The company has issued forward-looking statements regarding the efficacy of its pembrolizumab-based TRBC fusion molecules, acknowledging the inherent risks and uncertainties in achieving anticipated results.
HCW Biologics Scientists to Showcase Three Posters at the 40th Annual Society for Immunotherapy of Cancer Meeting
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies targeting chronic inflammation and related diseases, with a proprietary TRBC platform for creating various immunotherapeutic compounds.
Upcoming Presentations: The company will present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer from November 5 to 9, 2025, showcasing their lead drug candidates and their potential applications in cancer therapy.